A Study evaluating the magnitude and distribution of neuro-inflammation using [11C]PK11195 PET in patients with Alzheimer's disease and Progressive Supranuclear Palsy

Trial Profile

A Study evaluating the magnitude and distribution of neuro-inflammation using [11C]PK11195 PET in patients with Alzheimer's disease and Progressive Supranuclear Palsy

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Carbon-11 PK 11195 (Primary)
  • Indications Alzheimer's disease; Progressive supranuclear palsy
  • Focus Diagnostic use
  • Acronyms NIMROD
  • Most Recent Events

    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
    • 14 Jul 2017 New trial record
    • 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top